Abstract
During the last decennium, the role of bone marrow mononuclear cells (BMMC) has been underscored in the healing process after acute myocardial infarction (AMI). Although these cells improve left ventricular recovery after AMI in experimental studies, results from large-scale randomised trials investigating BMMC therapy in patients with AMI have shown contradictory results. To address this issue the HEBE study was designed, a multicentre, randomised trial, evaluating the effects of intracoronary infusion of BMMCs and the effects of intracoronary infusion of peripheral blood mononuclear cells after primary percutaneous coronary intervention. The primary endpoint of the HEBE trial is the change in regional myocardial function in dysfunctional segments at four months relative to baseline, based on segmental analysis as measured by magnetic resonance imaging. The results from the HEBE trial will provide detailed information about the effects of intracoronary BMMC therapy on post-infarct left ventricular recovery. In addition, further analysis of the data and material obtained may provide important mechanistic insights into the contribution of BMMCs to natural recovery from AMI as well as the response to cell therapy. This may significantly contribute to the development of improved cell-based therapies, aiming at optimising post-infarct recovery and preventing heart failure. (Neth Heart J 2008;16:436-9.)
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM, et al. Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation 2002;106:2351-7.
Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-72.
Massa M, Rosti V, Ferrario M, Campanelli R, Ramajoli I, Rosso R, et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 2005;105:199-206.
Kucia M, Dawn B, Hunt G, Guo Y, Wysoczynski M, Majka M, et al. Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. Circ Res 2004;95:1191-9.
Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol 2008;28:208-16.
van den Bos EJ, van der Giessen WJ, Duncker DJ. Cell transplantation for cardiac regeneration: where do we stand? Neth Heart J 2008;16:88-95.
Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-5.
Quaini F, Urbanek K, Beltrami AP, Finato N, Beltrami CA, Nadal-Ginard B, et al. Chimerism of the transplanted heart. N Engl J Med 2002;346:5-15.
Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Amano K, Iba O, et al. Improvement of collateral perfusion and regional function by implantation of peripheral blood mononuclear cells into ischemic hibernating myocardium. Arterioscler Thromb Vasc Biol 2002;22:1804-10.
Assmus B, Schachinger V, Teupe C, Britten M, Lehmann R, Dobert N, et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002;106:3009-17.
Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breiden-bach C, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004;364:141-8.
Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355:1210-21.
Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 2006;27:2775-83.
Lunde K, Solheim S, Aakhus S, Arnesen H, Abdelnoor M, Forfang K. Autologous stem cell transplantation in acute myocardial infarction: The ASTAMI randomized controlled trial. Intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects. Scand Cardiovasc J 2005;39:150-8.
Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 2007;28:766-72.
van Beem RT, Hirsch A, Lommerse IM, Zwaginga JJ, Noort WA, Biemond BJ, et al. Recovery and functional activity of mononuclear bone marrow and peripheral blood cells after different cell isolation protocols used in clinical trials for cell therapy after acute myocardial infarction. Eurointervention 2008;4:133-8.
Hirsch A, Nijveldt R, van der Vleuten PA, Biemond BJ, Doevendans PA, van Rossum AC et al. Intracoronary infusion of autologous mononuclear bone marrow cells or peripheral mononuclear blood cells after primary percutaneous coronary intervention: rationale and design of the HEBE trial – a prospective, multicenter, randomized trial. Am Heart J 2006;152:434-41.
Kamihata H, Matsubara H, Nishiue T, Fujiyama S, Amano K, Iba O, et al. Improvement of collateral perfusion and regional function by implantation of peripheral blood mononuclear cells into ischemic hibernating myocardium. Arterioscler Thromb Vasc Biol 2002;22:1804-10.
Hirsch A, Nijveldt R, van der Vleuten PA, Tio RA, van der Giessen WJ, Marques KM, et al. Intracoronary infusion of autologous mononuclear bone marrow cells in patients with acute myocardial infarction treated with primary PCI: Pilot study of the multicenter HEBE trial. Catheter Cardio-vasc Interv 2008;71:273-81.
Author information
Authors and Affiliations
Additional information
Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam and Interuniversity Cardiology Institute of the Netherlands, Utrecht, the Netherlands
Department of Cardiology, VU University Medical Center, Amsterdam and Interuniversity Cardiology Institute of the Netherlands, Utrecht, the Netherlands
Department of Cardiology, University Medical Center Groningen, Groningen and Interuniversity Cardiology Institute of the Netherlands, Utrecht, the Netherlands
Department of Cardiology, Erasmus University Medical Center, Rotterdam and Interuniversity Cardiology Institute of the Netherlands, Utrecht, the Netherlands
Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands
Department of Cardiology, University Hospital Maastricht, Maastricht, the Netherlands
Department of Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands
Department of Cardiology, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands
Department of Experimental Immunohaematology, Sanquin Research, Amsterdam and Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands
Department of Haematology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
Department of Cardiology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands
Correspondence to: J.J. Piek
Academic Medical Center, Department of Cardiology, Room B2-250, PO Box 22600, 1100 DD Amsterdam, the Netherlands
Rights and permissions
About this article
Cite this article
van der Laan, A.M., Hirsch, A., Nijveldt, R. et al. Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results. NHJL 16, 436–439 (2008). https://doi.org/10.1007/BF03086194
Issue Date:
DOI: https://doi.org/10.1007/BF03086194